ST.
PAUL, Minn., Sept. 18,
2024 /PRNewswire/ -- ScaleReady™, in collaboration
with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ:
TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a
Singapore-U.S. based TCR-T therapy company) has been awarded a
G-Rex® Grant. ImmunoScape's $250,000 G-Rex® Grant will enable
process development and IND enabling studies of their novel
WT1-targeted TCR-T cell therapy.
"We are thankful for ScaleReady's G-Rex Grant Program and are
grateful to receive an award that will substantially defray the
time and cost of bringing our novel therapy into the clinic," said
Dr. Tania Ribeiro, Senior Director
and Head of CMC.
"We are proud to award ImmunoScape a G-Rex Grant to facilitate
the clinical readiness of their novel TCR-T cell therapy.
Expediting the pathway to generating meaningful clinical data that
their investors need to see is a primary objective of the G-Rex
Grant Program. We are happy to see more private sector groups like
ImmunoScape leveraging this unique program." said John Wilson, CEO of Wilson Wolf and co-inventor of
G-Rex®.
As part of the G-Rex® Grant, ImmunoScape plans to
complete their pre-clinical process development including the
incorporation of Wilson Wolf's fully
closed-system G-Rex® bioreactors. ImmunoScape will also get early
access to a new line of GMP cytokines from Bio-Techne that are
tailor-made for use with G-Rex. These new offerings, called
ProPak™ GMP Cytokines, are designed to streamline reagent
preparation and administration in a GMP manufacturing
setting. The new products will help companies like
ImmunoScape save thousands of dollars per manufacturing run, while
simplifying and streamlining processes for reduced variability.
Additionally, ImmunoScape's G-Rex Grant will help facilitate the
technology transfer of their G-Rex centric manufacturing process to
their contract development and manufacturing organization (CDMO)
partner. The G-Rex Grant will support training runs and
engineering runs that will be used to generate the manufacturing
batch records for an IND data package submission to the FDA, slated
to occur in 2026.
ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and
gene-modified cell therapy (CGT) development and manufacturing by
awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain
access to exclusive support from ScaleReady's growing consortium of
G-Rex Grant Partners who bring best-in-class tools and technologies
as well as unparalleled knowledge and expertise in the areas of
cGMP manufacturing, quality and regulatory affairs, CGT business
operations, and more.
About ImmunoScape
ImmunoScape is a biotechnology
company developing next-generation TCR-T cell therapies for the
treatment of solid tumors. By leveraging Deep Immunomics and
AI-driven insights, ImmunoScape is focused on identifying TCRs with
superior therapeutic potential, selecting the best candidates for
clinical development. With multiple programs in the discovery and
preclinical stages, the company is performing IND-enabling studies
and preparing for the lead program to enter into the clinic and
exploring strategic partnerships that align with our mission to
bring next-generation TCR-T therapies to more patients. For more
information, please visit https://immunoscape.com/.
About ScaleReady
ScaleReady provides the field
of cell and gene-modfied cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly
growing list of over 800 organizations and is producing drug
products for approximately 50% of CGT clinical trials as well as 4
commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
For more information about the ScaleReady G-Rex®
Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to
simplifying cell and gene-modified cell (CGT) therapy research,
process development, and manufacturing. This is being accomplished
through its scalable G-Rex® technology, which is used throughout
the world in CGT applications ranging from basic research to
commercial drug production.
Wilson Wolf's mission is to
create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic communities. Bio-Techne, in partnership with
Wilson Wolf, is creating products
such as media and cytokines that are specifically tailored to
G-Rex® Bioreactors, including right-sized reagent
quantities in containers that are tailored to high throughput
closed-system manufacturing. For more information on Bio-Techne and
its brands, please visit https://www.bio-techne.com or
follow the Company on social media
at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and
only G-Rex® centric contract development and
manufacturing organization (CDMO) specializing in G-Rex® based cell
and gene-modified cell therapy development and manufacturing. The
company offers a wide range of services to support the development
and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one
G-Rex® process at a time.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immunoscape-302250120.html
SOURCE Bio-Techne Corporation
